Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902928 | 0.94 | TSHR (0.36) | TSHRACSS2 | |
| SCHEMBL4905168 | 0.92 | TSHR (0.35) | TSHRPOLBADRB2HTTSMN1; SMN2 | |
| SCHEMBL4883328 | 0.87 | TSHR (0.33) | TSHRPOLBADRB2HTTSMN1; SMN2 | |
| SCHEMBL4901053 | 0.86 | TSHR (0.37) | TSHRACSS2 | |
| SCHEMBL4896718 | 0.83 | MAOB (0.34) | — | |
| SCHEMBL4879792 | 0.82 | — | — | |
| SCHEMBL4890931 | 0.81 | TSHR (0.35) | TSHRACSS2 | |
| SCHEMBL4884136 | 0.80 | SMN1; SMN2 (0.31) | TSHRPOLBADRB2HTTSMN1; SMN2 | |
| SCHEMBL4903034 | 0.78 | NOS2 (0.36) | TSHR | |
| SCHEMBL4884251 | 0.78 | ALDH1A1 (0.31) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| EP-1838679-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | Pfizer Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072833-A1 | IMIDAZOLE DERIVATIVES AS ENZYME REVERSE TRANSCRIPTASE MODULATORS | PFIZER LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | TSHR 1981/4885POLB 13/4885ADRB2 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.